Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goss, P. E.
Right arrow Articles by Strasser, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goss, P. E.
Right arrow Articles by Strasser, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 19, Issue 3 (February), 2001: 881-894
© 2001 American Society for Clinical Oncology

REVIEW ARTICLES

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

By Paul E. Goss, Kathrin Strasser

From the Division of Hematology/Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.

Address reprint requests to Paul E. Goss, MD, PhD, Division of Hematology/Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada; email: pegoss{at}interlog.com

PURPOSE: The purpose of this article is to provide an overview of the current clinical status and possible future applications of aromatase inhibitors in breast cancer.

METHODS: A review of the literature on the third-generation aromatase inhibitors was conducted. Some data that have been presented but not published are included. In addition, the designs of ongoing trials with aromatase inhibitors are outlined and the implications of possible results discussed.

RESULTS: All of the third-generation oral aromatase inhibitors—letrozole, anastrozole, and vorozole (nonsteroidal, type II) and exemestane (steroidal, type I)—have now been tested in phase III trials as second-line treatment of postmenopausal hormone-dependent breast cancer. They have shown clear superiority compared with the conventional therapies and are therefore considered established second-line hormonal agents. Currently, they are being tested as first-line therapy in the metastatic, adjuvant, and neoadjuvant settings. Preliminary results suggest that the inhibitors might displace tamoxifen as first-line treatment, but further studies are needed to determine this.

CONCLUSION: The role of aromatase inhibitors in premenopausal breast cancer and in combination with chemotherapy and other anticancer treatments are areas of future exploration. The ongoing adjuvant trials will provide important data on the long-term safety of aromatase inhibitors, which will help to determine their suitability for use as chemopreventives in healthy women at risk of developing breast cancer.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
R. J. Santen, H. Brodie, E. R. Simpson, P. K. Siiteri, and A. Brodie
History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target
Endocr. Rev., June 1, 2009; 30(4): 343 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. C. Jordan
A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention
Cancer Res., February 15, 2009; 69(4): 1243 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. C. Jordan
The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death?
J. Clin. Oncol., June 20, 2008; 26(18): 3073 - 3082.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Goss, I. N. Bondarenko, G. N. Manikhas, K. B. Pendergrass, W. H. Miller Jr, P. Langecker, and D. Blanchett
Phase III, Double-Blind, Controlled Trial of Atamestane Plus Toremifene Compared With Letrozole in Postmenopausal Women With Advanced Receptor-Positive Breast Cancer
J. Clin. Oncol., November 1, 2007; 25(31): 4961 - 4966.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Lupu and J. A. Menendez
Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?
Endocrinology, September 1, 2006; 147(9): 4056 - 4066.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. I. Pritchard
Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?
Ann. Onc., July 1, 2006; 17(7): 1035 - 1036.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
F Labrie
Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 335 - 355.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Altundag and N. K. Ibrahim
Aromatase inhibitors in breast cancer: an overview.
Oncologist, June 1, 2006; 11(6): 553 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Shin, T. Miller, and C. L. Arteaga
ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors
Clin. Cancer Res., February 1, 2006; 12(3): 1008s - 1012s.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. E. Goss, J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, D. Tu, L. E. Shepherd, K. I. Pritchard, et al.
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
J Natl Cancer Inst, September 7, 2005; 97(17): 1262 - 1271.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz
Aromatase Inhibitors in the Treatment of Breast Cancer
Endocr. Rev., May 1, 2005; 26(3): 331 - 345.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. C. Jordan
Chemoprevention in the 21st Century: Is a Balance Best or Should Women Have No Estrogen at All?
J. Clin. Oncol., March 10, 2005; 23(8): 1598 - 1600.
[Full Text] [PDF]

Home page
 JCOHome page
K. Strasser-Weippl and P. E. Goss
Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
J. Clin. Oncol., March 10, 2005; 23(8): 1751 - 1759.
[Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, C. Hudis, H. J. Burstein, A. C. Wolff, K. I. Pritchard, J. N. Ingle, R. T. Chlebowski, R. Gelber, S. B. Edge, J. Gralow, et al.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004
J. Clin. Oncol., January 20, 2005; 23(3): 619 - 629.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. K. Dunn, D. L. Wickerham, and L. G. Ford
Prevention of Hormone-Related Cancers: Breast Cancer
J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Morales, D. Timmerman, P. Neven, M. L. Konstantinovic, A. Carbonez, S. Van Huffel, L. Ameye, C. Weltens, M.-R. Christiaens, I. Vergote, et al.
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients
Ann. Onc., January 1, 2005; 16(1): 70 - 74.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
C. Osipo, H. Liu, K. Meeke, and V. C. Jordan
The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death
Experimental Biology and Medicine, September 1, 2004; 229(8): 722 - 731.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Rock, S. W. Flatt, C. A. Thomson, M. L. Stefanick, V. A. Newman, L. A. Jones, L. Natarajan, C. Ritenbaugh, K. A. Hollenbach, J. P. Pierce, et al.
Effects of a High-Fiber, Low-Fat Diet Intervention on Serum Concentrations of Reproductive Steroid Hormones in Women With a History of Breast Cancer
J. Clin. Oncol., June 15, 2004; 22(12): 2379 - 2387.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
H. T. Mouridsen and N. Brunner
Clinical Infrastructures to Support Proteomic Studies of Tissue and Fluids in Breast Cancer
Mol. Cell. Proteomics, April 1, 2004; 3(4): 302 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. E. Goss and K. Strasser-Weippl
Prevention Strategies with Aromatase Inhibitors
Clin. Cancer Res., January 1, 2004; 10(1): 372S - 379S.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Jones
Combining trastuzumab (Herceptin(R)) with hormonal therapy in breast cancer: what can be expected and why?
Ann. Onc., December 1, 2003; 14(12): 1697 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. E. Goss, J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, D. Tu, L. E. Shepherd, K. I. Pritchard, et al.
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
N. Engl. J. Med., November 6, 2003; 349(19): 1793 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. A. Haiman, D. O. Stram, M. C. Pike, L. N. Kolonel, N. P. Burtt, D. Altshuler, J. Hirschhorn, and B. E. Henderson
A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort
Hum. Mol. Genet., October 16, 2003; 12(20): 2679 - 2692.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. C. Ciobanu, V. Luu-The, C. Martel, F. Labrie, and D. Poirier
Inhibition of Estrone Sulfate-induced Uterine Growth by Potent Nonestrogenic Steroidal Inhibitors of Steroid Sulfatase
Cancer Res., October 1, 2003; 63(19): 6442 - 6446.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. E. Smith and M. Dowsett
Aromatase Inhibitors in Breast Cancer
N. Engl. J. Med., June 12, 2003; 348(24): 2431 - 2442.
[Full Text] [PDF]

Home page
 NEJMHome page
B. L. Riggs and L. C. Hartmann
Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice
N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. U. Buzdar
Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors
Clin. Cancer Res., January 1, 2003; 9(1): 468S - 472S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Ingle
Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 480S - 485S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. A. Emens and N. E. Davidson
Adjuvant Hormonal Therapy for Premenopausal Women with Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 486S - 494S.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Hui, G. L. Finney, J. S. Carroll, C. S. L. Lee, E. A. Musgrove, and R. L. Sutherland
Constitutive Overexpression of Cyclin D1 but not Cyclin E Confers Acute Resistance to Antiestrogens in T-47D Breast Cancer Cells
Cancer Res., December 1, 2002; 62(23): 6916 - 6923.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Rock and W. Demark-Wahnefried
Nutrition and Survival After the Diagnosis of Breast Cancer: A Review of the Evidence
J. Clin. Oncol., August 1, 2002; 20(15): 3302 - 3316.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002
J. Clin. Oncol., August 1, 2002; 20(15): 3317 - 3327.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister
American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. J. Santen
To Block Estrogen's Synthesis or Action: That Is the Question
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3007 - 3012.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Bowman, H. Gabra, S. P. Langdon, A. Lessells, M. Stewart, A. Young, and J. F. Smyth
CA125 Response Is Associated with Estrogen Receptor Expression in a Phase II Trial of Letrozole in Ovarian Cancer: Identification of an Endocrine-sensitive Subgroup
Clin. Cancer Res., July 1, 2002; 8(7): 2233 - 2239.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
P. Boasberg
Medical Oncology Analysis
Integr Cancer Ther, June 1, 2002; 1(2): 182 - 184.
[PDF]

Home page
 JCOHome page
C. L. Harper-Wynne, N. P.M. Sacks, K. Shenton, F. A. MacNeill, P. Sauven, I. J. Laidlaw, Z. Rayter, S. Miall, A. Howes, J. Salter, et al.
Comparison of the Systemic and Intratumoral Effects of Tamoxifen and the Aromatase Inhibitor Vorozole in Postmenopausal Patients With Primary Breast Cancer
J. Clin. Oncol., February 15, 2002; 20(4): 1026 - 1035.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. T. Chlebowski, E. Aiello, and A. McTiernan
Weight Loss in Breast Cancer Patient Management
J. Clin. Oncol., February 15, 2002; 20(4): 1128 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. A. Bennett, F. B. Mesfin, T. T. Andersen, J. F. Gierthy, and H. I. Jacobson
A peptide derived from alpha -fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen
PNAS, January 31, 2002; (2002) 251667098.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
E. R. Simpson and M. Dowsett
Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy
Recent Prog. Horm. Res., January 1, 2002; 57(1): 317 - 338.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. M. Qian, X. J. Sun, M. H. Tong, X. P. Li, J. Richa, and W.-C. Song
Targeted Disruption of the Mouse Estrogen Sulfotransferase Gene Reveals a Role of Estrogen Metabolism in Intracrine and Paracrine Estrogen Regulation
Endocrinology, December 1, 2001; 142(12): 5342 - 5350.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
P. E. Lonning
Aromatase inhibitors and inactivators in breast cancer
BMJ, October 20, 2001; 323(7318): 880 - 881.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Buzdar and A. Howell
Advances in Aromatase Inhibition: Clinical Efficacy and Tolerability in the Treatment of Breast Cancer
Clin. Cancer Res., September 1, 2001; 7(9): 2620 - 2635.
[Full Text] [PDF]

Home page
 JCOHome page
P. P. Donnellan, S. L. Douglas, D. A. Cameron, and R. C.F. Leonard
Aromatase Inhibitors and Arthralgia
J. Clin. Oncol., May 15, 2001; 19(10): 2767 - 2767.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. A. Bennett, F. B. Mesfin, T. T. Andersen, J. F. Gierthy, and H. I. Jacobson
A peptide derived from alpha -fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen
PNAS, February 19, 2002; 99(4): 2211 - 2215.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online